Lifecore Biomedical, INC \de\ DEF 14A proxy statements

Lifecore Biomedical, Inc. has filed its 2026 proxy statement, outlining proposals for director elections, auditor ratification, executive compensation, and a new 2026 Stock Incentive Plan.

Lifecore Biomedical, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on October 29, 2025, addressing director elections, auditor ratification, and executive compensation.

Lifecore Biomedical is holding a special meeting of stockholders to approve the issuance of shares underlying Series A Convertible Preferred Stock, aiming to remove a conversion limit and potentially increase the voting power of preferred stockholders.

Lifecore Biomedical plans a special meeting on April 10, 2025, to seek stockholder approval for removing the exchange cap on its Series A Convertible Preferred Stock.

Lifecore Biomedical announces its 2024 Annual Meeting of Stockholders to be held virtually on November 7, 2024, covering director elections, auditor ratification, and executive compensation.

Lifecore Biomedical amends its proxy statement to reflect changes in Delaware law regarding the voting standard for increasing authorized shares and corrects a typographical error in the proposed amendment language.

Lifecore Biomedical is asking stockholders to vote on proposals to declassify the board of directors, increase the number of authorized common shares, and approve executive compensation and stock incentive plans at its upcoming annual meeting.